Bank Hapoalim BM decreased its holdings in shares of Sanofi (NYSE:SNY) by 9.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,294 shares of the company’s stock after selling 2,150 shares during the quarter. Bank Hapoalim BM’s holdings in Sanofi were worth $972,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Harbour Capital Advisors LLC acquired a new position in Sanofi during the first quarter worth $113,000. Parallel Advisors LLC boosted its holdings in Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the last quarter. Eagle Ridge Investment Management acquired a new position in Sanofi during the second quarter worth $160,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in Sanofi by 6,188.3% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after purchasing an additional 3,713 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. boosted its holdings in Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares during the last quarter. Institutional investors and hedge funds own 9.33% of the company’s stock.

Shares of Sanofi (NYSE:SNY) traded down 0.60% during mid-day trading on Friday, reaching $48.43. 2,378,561 shares of the company’s stock were exchanged. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The company has a market cap of $121.63 billion, a PE ratio of 11.54 and a beta of 0.88. The company’s 50-day moving average price is $48.30 and its 200 day moving average price is $47.32.

Sanofi (NYSE:SNY) last posted its earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. The company’s revenue was down 2.3% on a year-over-year basis. On average, equities research analysts predict that Sanofi will post $3.34 EPS for the current year.

In other news, major shareholder Sanofi bought 105,820 shares of Sanofi stock in a transaction dated Thursday, August 24th. The stock was purchased at an average price of $482.04 per share, for a total transaction of $51,009,472.80. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 1.00% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/17/bank-hapoalim-bm-sells-2150-shares-of-sanofi-sny.html.

Several research analysts recently commented on SNY shares. BidaskClub cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research note on Friday, June 2nd. HSBC Holdings plc upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research note on Friday. Finally, Argus reiterated a “buy” rating and issued a $55.00 price target on shares of Sanofi in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $54.00.

Sanofi Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.